File size: 3,157 Bytes
9eabfc4 16fe403 9eabfc4 16fe403 |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 |
---
language:
- en
bigbio_language:
- English
license: cc0-1.0
bigbio_license_shortname: cc0-1.0
multilinguality: monolingual
pretty_name: CZI DRSM
homepage: https://github.com/chanzuckerberg/DRSM-corpus
bigbio_pubmed: false
bigbio_public: true
bigbio_tasks:
- TXTCLASS
---
# Dataset Card for CZI DRSM
[README.md](..%2Fmed_qa%2FREADME.md)
## Dataset Description
- **Homepage:** https://github.com/chanzuckerberg/DRSM-corpus
- **Pubmed:** False
- **Public:** True
- **Tasks:** TXTCLASS
Research Article document classification dataset based on aspects of disease research. Currently, the dataset consists of three subsets:
(A) classifies title/abstracts of papers into most popular subtypes of clinical, basic, and translational papers (~20k papers);
- Clinical Characteristics, Disease Pathology, and Diagnosis -
Text that describes (A) symptoms, signs, or ‘phenotype’ of a disease;
(B) the effects of the disease on patient organs, tissues, or cells;
(C) the results of clinical tests that reveal pathology (including
biomarkers); (D) research that use this information to figure out
a diagnosis.
- Therapeutics in the clinic -
Text describing how treatments work in the clinic (but not in a clinical trial).
- Disease mechanism -
Text that describes either (A) mechanistic involvement of specific genes in disease
(deletions, gain of function, etc); (B) how molecular signalling or metabolism
binding, activating, phosphorylation, concentration increase, etc.)
are involved in the mechanism of a disease; or (C) the physiological
mechanism of disease at the level of tissues, organs, and body systems.
- Patient-Based Therapeutics -
Text describing (A) Clinical trials (studies of therapeutic measures being
used on patients in a clinical trial); (B) Post Marketing Drug Surveillance
(effects of a drug after approval in the general population or as part of
‘standard healthcare’); (C) Drug repurposing (how a drug that has been
approved for one use is being applied to a new disease).
(B) identifies whether a title/abstract of a paper describes substantive research into Quality of Life (~10k papers);
- -1 - the paper is not a primary experimental study in rare disease
- 0 - the study does not directly investigate quality of life
- 1 - the study investigates qol but not as its primary contribution
- 2 - the study's primary contribution centers on quality of life measures
(C) identifies if a paper is a natural history study (~10k papers).
- -1 - the paper is not a primary experimental study in rare disease
- 0 - the study is not directly investigating the natural history of a disease
- 1 - the study includes some elements a natural history but not as its primary contribution
- 2 - the study's primary contribution centers on observing the time course of a rare disease
These classifications are particularly relevant in rare disease research, a field that is generally understudied.
## Citation Information
```
# N/A
```
|